^
Association details:
| Biomarker: | ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation
Published date:
10/21/2020
Excerpt:
A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma... The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib....After 17 months treatment of crizotinib, the chest CT scan shows the progression of the left lung adenocarcinoma. We then performed the re-biopsy and sequencing data showed an ALK exon 23 C1156Y missense mutation which is a known mechanism for resistance against crizotinib, in addition to LOC101927285-ALK mutation.
DOI:
10.4143/crt.2020.952
